drugset
drugset / Trial / NCT03217734

MAP Study: Methotrexate and Adalimumab in Psoriasis

NCT03217734 ↗

Phase 2/3 Completed 56 enrolled Jeffrey J Crowley MD AbbVie · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Assess the efficacy and safety of ADA compared to ADA/MTX in patient with Psoriasis. Compare Anti-ADA antibody formation and serum ADA levels in patients on ADA compared with those on combination ADA and MTX.

Timeline

Start
2017-04-10
Primary completion
2018-12-31
Completion
2018-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adalimumab Monoclonal antibody 40 mg Subcutaneous
Comparator Methotrexate Small molecule 10 mg Oral

Indications

psoriasis